Costs of Research Sample Clauses

Costs of Research. ACTIVITY
Sample 1Sample 2
AutoNDA by SimpleDocs
Costs of Research. Subject to the remainder of this Clause 4.5 and the provisions of Clause 16 or unless expressly agreed to the contrary in writing by the unanimous agreement of all JSC Members, Immutep shall be responsible for the costs that it incurs in performing the activities allotted to it in the Research Plan. Notwithstanding, GSK shall pay to Immutep [***] within [***] following receipt by GSK of an Invoice from Immutep on or after the Effective Date. GSK shall subsequently pay to Immutep [***] within [***] following receipt by GSK of an Invoice from Immutep on or after the first annual anniversary of the Effective Date. However, if GSK terminates the Research Programme pursuant to this Agreement after the first payment of [***] and prior to the first anniversary , GSK shall not be required to pay Immutep the second payment of [***].
Sample 1
Costs of Research. With respect to the Collaboration Program for the Initial Target, all Research Activities will be conducted by Company (directly or through its Affiliates or Subcontractors) at Company’s sole cost and expense (except as set forth in Section 2.2.3 and Section 7.8 and as otherwise may be agreed by the Parties in writing) in accordance with the Research Plan. If Vertex exercises the Additional Target Option, then, with respect to the Collaboration Program for the Additional Target, Vertex shall reimburse Company in accordance with Section 7.8 for Company’s [***] incurred in conducting (directly or through its Affiliates or Subcontractors) the applicable Research Activities in accordance with the Research Plan and the Additional Target Research Budget, as the same may be updated or amended.
Sample 1
Costs of Research. 4.1. Rosetta agrees to bear [***] costs related to the performance of the experiments in relation to the Research Project, [***], all as indicated in the Budget Schedule of each Trial. The Budget Schedule of the first Trial specified in Protocol A1 is attached as Appendix B1.
Sample 1
Costs of Research. H9. AEM and KIA will fund the cost of any research and development that they jointly undertake in proportion to the benefit that each of them expects to receive from the commercial application of the technique or method that the research and development is expected to produce. SCHEDULE I: OPTION TO ACQUIRE MEADOWBANK MINE ASSETS Objective I1. The objective of this Schedule I is to establish a procedure whereby KIA may acquire assets that constitute part of the Meadowbank Mine.
Sample 1
Costs of Research. ACTIVITY The Research Provider shall promptly pay and discharge all costs incurred in the Research Activity. The Research Provider acknowledges that the Funding is the maximum amount that HRC will contribute to the costs of the Research Activity and that HRC will not under any circumstances fund any shortfall between the amount of the Funding and the actual costs of the Research Activity. PAYMENT OF FUNDING Subject to clauses 6.4 and 10, HRC will: fund the Research Provider for the services and outputs defined in the Objectives and the Research Activity to the maximum amount set out in the Third Schedule; issue appropriate buyer-created GST invoices and pay the amount it has agreed to Fund by direct credit to the Research Provider’s nominated bank account on the 20th of each month during the term of the Research Activity by monthly instalments as specified in the table of payments set out in the Third Schedule; and pay any third-party expenses actually incurred by the Research Provider which it has agreed in the Third Schedule to pay, by direct credit to the Research Provider’s nominated bank account within 5 Business Days of receipt by HRC of a claim for reimbursement with supporting GST invoices. The Research Provider confirms: it is GST-registered pursuant to the GST Act, its GST number is as stated in Part 9 of the First Schedule, and it will immediately notify HRC of any change to its registration status; that, pursuant to the buyer-created tax invoice rules and specifically section 24(2)(b) of the GST Act, it will not issue a tax invoice, credit note or debit note in respect of the funding payments provided for by this Contract; and it will retain a copy of the buyer-created tax invoices for its own records. Notwithstanding the provisions of clause 6.1 HRC shall be entitled to retain an amount equivalent to one month’s funding for each year of the term of the Contract from the Funding which HRC will pay to the Research Provider within 1 month of HRC confirming it is satisfied with the Post Completion Reports. HRC may withhold, vary or suspend any payment where it reasonably believes, after discussion between the parties, that the Research Provider has not complied with any of its obligations under this Contract. REPAYMENT OF UNSPENT FUNDING If the Post Completion Report discloses, or HRC discovers, that the actual expenditure by the Research Provider on the Research Activity is more than $10,000 less than the Funding that has been paid by HRC, the Re...
Sample 1

Related to Costs of Research

  • Development Costs With respect to activities prior to the Amendment Effective Date, each Party was to pay [*] of the total Direct Development Costs of a Product incurred in accordance with the Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.

  • Development Fees The character and amount of any fee, charge or other consideration which must be paid by Donee to develop any Property.

  • Development Expenses Novartis shall be solely responsible for the costs and expenses of Developing and commercializing Licensed Products pursuant to the terms of this Agreement, except with respect to Infinity’s research, development and commercialization activities with respect to an Abandoned Profile pursuant to Section 3.3.1 (subject to Section 2.3).

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Milestone Fees Licensee will pay Milestone Fees indicated in Section 3.1(b) of the Patent & Technology License Agreement by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events set forth in Section 3.1(b) of the Patent & Technology License Agreement are achieved.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Fee The fee for the packaging of a Company Property, including negotiating and approving plans and assisting in obtaining zoning and necessary variances and financing for a specific Company Property to be developed or under development, either initially or at a later date.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

Time is Money Join Law Insider Premium to draft better contracts faster.